Data from large real-world analyses demonstrate a lower incidence of moderate to severe COPD exacerbations, fewer hospital admissions, and reduced all-cause mortality in patients treated with SGLT2-i. Here, SLC5A2 is linked to chronic obstructive pulmonary disease.